Treatment of Recurrent Glioblastoma Multiforme (rGBM) with Antineoplaston AS2-1 in Combination with Targeted Therapy
Cancer and Clinical Oncology · 29.01.2019 · 8 (1) · 1
DOI: 10.5539/cco.v8n1p1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer and Clinical Oncology, online erschienen am 29.01.2019. Verfasst von Stanislaw R. Burzynski und 2 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Treatment of recurrent glioblastoma multiforme (rGBM) poses a difficult challenge. Therefore, the purpose of this report was to evaluate objective response (OR), progression-free survival (PFS), overall survival (OS), and the incidence of adverse events (AEs) in rGBM patients, age 19-70 years, who were treated with antineoplaston AS2-1 (Astugenal) plus targeted therapy. A retrospective analysis was performed. Tumor response was assessed by gadolinium-enhanced magnetic resonance imaging (MRI). Twenty-nine adult rGBM patients were treated between 9/11/2015 and 06/23/2018. Seven had no prior treatment with bevacizumab elsewhere, had radiologic evidence of rGBM, and had MRI assessment of tumor response. The median treatment time was 101 days (range: 55-208 days). OR was seen in six patients (85.7%) with complete disappearance of gadolinium enhancement in four patients (57.1%) and a 50% or greater reduction in gadolinium enhancement in two patients (28.6%). Progressive disease was seen in one patient (14.3%). The median time to first response was 29 days (range: 22-96 days) while the median duration of response was 141 days (range 55-739+ days). Six- and 12-month PFS was 57% and 19%, respectively while 6- and 12-month OS at was 86% and 54%, respectively. Treatment was well-tolerated with no patients experiencing grade 3 or 4 antineoplaston-related toxicity. Regarding response to treatment and toxicity, AS2-1 plus targeted therapy compares favorably with other reported rGBM therapies. Duration of response was shortened by the ill-advised decision of some patients to discontinue treatment after a tumor response was achieved.
Zitieren
APA
Burzynski, S. R., Janicki, T., & Beenken, S. (2019). Treatment of Recurrent Glioblastoma Multiforme (rGBM) with Antineoplaston AS2-1 in Combination with Targeted Therapy. Cancer and Clinical Oncology, 8(1), 1. https://doi.org/10.5539/cco.v8n1p1
Vancouver
Burzynski SR, Janicki T, Beenken S. Treatment of Recurrent Glioblastoma Multiforme (rGBM) with Antineoplaston AS2-1 in Combination with Targeted Therapy. Cancer and Clinical Oncology. 2019;8(1):1. doi:10.5539/cco.v8n1p1
BibTeX
@article{Burzynski2019,
author = {Burzynski, Stanislaw R. and Janicki, Tomasz and Beenken, Samuel},
title = {Treatment of Recurrent Glioblastoma Multiforme (rGBM) with Antineoplaston AS2-1 in Combination with Targeted Therapy},
journal = {Cancer and Clinical Oncology},
year = {2019},
volume = {8},
number = {1},
pages = {1},
doi = {10.5539/cco.v8n1p1}
}
EUVIMED